Biba Cancer Research Foundation benefits from several collaborations, where others’ ground-breaking achievements and continued support have enabled our research progress and fueled our growth.
Cullis Lab & NanoCore, Nanomedicine Innovation Network (NMIN) One of our most promising brain cancer drug candidates utilizes lipid nanoparticle (LNP) technology, repurposing the FDA-approved formulation of Onpattro1, which was originally developed for treating a rare disease of hereditary transthyretin amyloidosis. This LNP system led to the revised mRNA formulation by Acuitas Therapeutics (a biotech company co-founded by Dr. Pieter Cullis) for the Pfizer/BioNTech COVID-19 vaccine2. Read more about Dr. Cullis3, the NanoCore led by Dr. Witzigmann4, and LNP`s contribution to the most widely-distributed medication of today5.
Lab2Launch, entrepreneurship@UBC (University of British Columbia)
entrepreneurship@UBC propels UBC innovations out into the world through venture creation, providing UBC students, researchers, faculty members, alumni and staff with the resources, networks, and funding they need to succeed.
entrepreneurship@UBC’s Lab2Launch Venture Building program is for UBC researchers and scientists who are focusing on the development of a scientific or technological innovation which is unique, proprietary and difficult to reproduce, propelling them through venture creation, team building, investment and growth.
